Teladoc Health, Inc.

TDOCUS

Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.

Founded2002IPO year2015As of2026-08-04
Market Cap
$1.19B
Enterprise Value
$1.44B
EV / LTM Revenue
0.6x
EV / NTM Revenue
0.6x
Trading multiples

Enterprise value over trailing (LTM) vs. forward (NTM) fundamentals. Click an LTM cell to chart it.

LTM
trailing
NTM
forward
Revenue
0.6x
Gross Profit
0.8x
EBITDA
4.4x
Classification
Sector
Healthcare Services
Sub-sector
Virtual Care & Digital Health
Listing
TDOC
Country
US
Historical valuation & fundamentals

EV / LTM Revenue

Annual financials & analyst forecasts

$MCY2021CY2022CY2023CY2024CY2025CY2026ECY2027E
Revenue YoY18%8%-1%-2%-4%0%
Revenue$2.03B$2.41B$2.60B$2.57B$2.53B$2.44B$2.44B
Gross Profit$1.38B$1.66B$1.84B$1.82B$1.76B
Gross Profit Margin68.0%69.1%70.8%70.8%69.5%
EBITDA($46M)($15M)$44M$32M$10M$325M$326M
EBITDA Margin-2.3%-0.6%1.7%1.2%0.4%13.3%13.3%
EBIT($266M)($13.65B)($249M)($1.02B)($263M)($121M)($121M)
Net Income($429M)($13.66B)($220M)($1.00B)($200M)($159M)($119M)
Free Cash Flow$185M$173M$307M$230M$228M
FCF Margin9.1%7.2%11.8%8.9%9.0%
Short-Term Debt$0M$14M$0M$551M$11M
Long-Term Debt$1.23B$1.54B$1.54B$991M$995M
Cash & Cash Equivalents$893M$918M$1.12B$1.30B$781M
Net Debt$332M$631M$415M$244M$225M
Net Debt / EBITDA9.5x7.7x23.3x
Rule of 4025.6%19.9%7.7%7.5%
Figures in $M. True calendar years (Jan–Dec) built from quarterly data — income & cash-flow lines summed across the four quarters, balance sheet as of year-end. E columns are calendarized analyst consensus — gross profit, cash flow and balance-sheet lines are not estimated. Net debt = short-term debt + long-term debt − cash & cash equivalents; Rule of 40 = YoY revenue growth + FCF margin.